

Pneumococcal Conjugate Vaccine (PCV13) (Continued)

<ul style="list-style-type: none"> • Children who received 1 or more doses of PCV7 (Prevnar®) should complete the series with PCV13 • Children aged 12-23 months who received 3 doses of PCV7 before 12 months of age should receive 1 dose of PCV13 (at least 8 weeks after last dose of PCV7) • A single supplemental dose of PCV13 is recommended for all children aged 14-59 months who received 4 doses of PCV7 and for high-risk children aged 60-71 months who received 4 doses of PCV7 • A single dose of PCV13 may also be administered to children aged 6-18 years who are at increased risk for pneumococcal disease • If both PCV13 and pneumococcal polysaccharide vaccine (PPV23) are indicated, give PPV23 at least 8 weeks after last dose of PCV13 	
<ul style="list-style-type: none"> • High-risk children: Those with sickle cell disease; anatomic or functional asplenia; chronic cardiac, pulmonary, or renal disease; diabetes mellitus; CSF leak; HIV infection; immune suppression; cochlear implants; bone marrow transplant. 	
Contraindications	<ul style="list-style-type: none"> • Serious allergic reaction to a prior dose or vaccine component • Moderate or severe acute illness
Special Considerations	<ul style="list-style-type: none"> • See Storage and Handling Section
VIS: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-PneumoConjugate.pdf	

FACTOID: Currently there are more than 90 known pneumococcal types; the 10 most common types account for about 62% of invasive disease worldwide.

Source: <http://www.nfid.org/factsheets/pneumofacts.shtml>